Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 11/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | STAT6 | P42226 | 1/20 | 0.36 |
| ▸ | USP1 | O94782 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5310034 | 0.88 | CYP1A2 (0.41) | CYP1A2CYP2C19RIPK1MEN1KMT2A | |
| SCHEMBL4899362 | 0.87 | MEN1 (0.42) | CYP1A2CYP2C19RIPK1MEN1KMT2A | |
| SCHEMBL4887310 | 0.84 | ADRA2A (0.37) | CYP1A2CYP2C19RIPK1MEN1KMT2A | |
| SCHEMBL4895013 | 0.84 | CRHR1 (0.39) | RIPK1MEN1KMT2A | |
| SCHEMBL4886170 | 0.83 | CYP1A2 (0.38) | CYP1A2CYP2C19RIPK1MEN1KMT2A | |
| SCHEMBL4889310 | 0.81 | RIPK1 (0.41) | RIPK1KMT2A | |
| SCHEMBL4891152 | 0.81 | PARK7 (0.36) | CYP1A2CYP2C19RIPK1MEN1KMT2A | |
| SCHEMBL3774144 | 0.79 | KMT2A (0.34) | RIPK1KMT2AGAA | |
| SCHEMBL4896111 | 0.78 | NPSR1 (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4886164 | 0.77 | MEN1 (0.39) | CYP1A2CYP2C19RIPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | CYP1A2 313/4885CYP2C19 227/4885RIPK1 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.